Mymetics's

• MYMX's Stock Performance relative to its Competitors

Argenx Se Share Performance +37.61% One Year

Argenx Se Profile Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions. More about Argenx Se's Market Share

Inovio Pharmaceuticals Inc Share Performance +10.85% Over The Past 5 Days

Inovio Pharmaceuticals Inc Profile Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of immunotherapies for the treatment of various diseases, including cancers and infectious diseases. Their business model involves leveraging their proprietary platforms, such as DNA-based technology and electroporation, to design and develop novel vaccines and therapies which are then advanced through clinical trials and potential partnerships for further commercialization. More about Inovio Pharmaceuticals Inc 's Market Share

Invivyd Inc Share Performance -27.54% One Year

Invivyd Inc Profile Invivyd Inc is a company that operates on a particular business model to deliver its products or services, but without providing any further details. More about Invivyd Inc 's Market Share

Moderna Inc Share Performance +196.68% This Quarter

Moderna Inc Profile Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases. More about Moderna Inc 's Market Share

Novavax inc Share Performance +10.37% Over The Past 5 Days

Novavax inc Profile Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market. More about Novavax inc 's Market Share

Sources: Mymetics Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 8, 2026 1:25 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mymetics Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.